EP0196920A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Degraded species of tissue-type plasminogen activator, pharmaceutical composition and method of preparation
Assignee: Beecham Group PLC
•
Filing: 1986-04-02
•
Granted: —
•
Expires: 2006-04-02
Abstract
Abstract A purified fibrinolytically active degraded species of tissue-type plasminogen activator comprising a fibrinolytically intact B chain of native t-PA linked to kringle 2 as the only functionally and structurally intact domain of native t-PA A chain.
Inventors
- 👤 Ian C/O Smithkline Beecham Pharmaceuticals Dodd
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-25 22:10
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; C12N9/6459; C12Y; C12Y304/00; C12Y304/21; C12Y304/21069; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
36 words
A purified fibrinolytically active degraded species of tissue-type plasminogen activator comprising a fibrinolytically intact B chain of native t-PA linked to kringle 2 as the only functionally and structurally intact domain of native t-PA A chain.
Claim 2
Dependent Claim
36 words
A purified fibrinolytically active degraded species of tissue-type plasminogen activator comprising a fibrinolytically intact B chain of native t-PA linked to kringle 2 as the only functionally and structurally intact domain of native t-PA A chain.
Claim 3
Dependent Claim
15 words
A species according to claim 1 having a molecular weight in the region of 38,000-40,000.
Claim 4
Dependent Claim
13 words
A species according to claim 2 having a molecular weight of around 38,000.
Claim 5
Dependent Claim
4 words
Purified alanine 160 t-PA.
Claim 6
Dependent Claim
4 words
Purified alanine 160 t-PA.
Claim 7
Dependent Claim
9 words
A derivative of a species of any preceeding claim.
Claim 8
Dependent Claim
22 words
A derivative according to claim 5, wherein any catalytic site essential for fibrinolytic activity is optionally blocked by a removable blocking group.
Claim 9
Dependent Claim
10 words
N'N'dimethyl 4-aminobenzoyl alanine 160 t-PA or p-anisoyl alanine 160 t-PA.
Claim 10
Dependent Claim
10 words
N'N'dimethyl 4-aminobenzoyl alanine 160 t-PA or p-anisoyl alanine 160 t-PA.
Claim 11
Dependent Claim
21 words
A pharmaceutical composition comprising a species according to any of claims 1 to 7 in combination with a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
18 words
A species according to any of claims 1 to 7 for use in the treatment of thrombotic diseases.
Claim 13
Dependent Claim
31 words
A method for the preparation of a species according to claim 1, which method comprises expressing DNA encoding said species in a recombinant host cell and recovering the degraded t-PA product.
Claim 14
Dependent Claim
31 words
A method for the preparation of a species according to claim 2, 3 or 4, which method comprises separating the species from native t-PA obtained from a t-PA secreting cell line.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.